QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

BMO Capital analyst Kostas Biliouris downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Market Perform and raises th...

Core News & Articles

Piper Sandler analyst Yasmeen Rahimi downgrades Tourmaline Bio (NASDAQ:TRML) from Overweight to Neutral and lowers the price...

Core News & Articles

Truist Securities analyst Robyn Karnauskas downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Hold and lowers the price tar...

Core News & Articles

Guggenheim analyst Yatin Suneja downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price target from...

Core News & Articles

HC Wainwright & Co. analyst Yi Chen downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price tar...

Core News & Articles

Chardan Capital analyst Daniil Gataulin downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Neutral and lowers the price tar...

Core News & Articles

LifeSci Capital analyst Rami Katkhuda downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Market Perform and announce...

Core News & Articles

Jefferies analyst Roger Song downgrades Tourmaline Bio (NASDAQ:TRML) from Buy to Hold and lowers the price target from $64 t...

Core News & Articles

Wedbush analyst Laura Chico downgrades Tourmaline Bio (NASDAQ:TRML) from Outperform to Neutral and maintains the price targe...

 novartis-to-expand-heart-drug-portfolio-with-14-billion-tourmaline-bio-acquisition

Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardi...

Core News & Articles

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option fo...

Core News & Articles

Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across cli...

Core News & Articles

Chardan Capital analyst Daniil Gataulin maintains Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $70 price target.

Core News & Articles

Guggenheim analyst Yatin Suneja reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $55 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION